Vir Biotechnology Announces Pricing of Public Offering of Common Stock

Vir Biotechnology Announces Pricing of Public Offering of Common Stock




Vir Biotechnology Announces Pricing of Public Offering of Common Stock

SAN FRANCISCO–(BUSINESS WIRE)–Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer, today announced the pricing of its underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $10.00 per share. The gross proceeds to Vir Biotechnology from the offering are expected to be $150 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Vir Biotechnology has granted the underwriters a 30-day option to purchase up to an additional 2,250,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the offering are being sold by Vir Biotechnology. Closing of the offering is expected to occur on November 16, 2026, subject to customary closing conditions.


Leerink Partners, Morgan Stanley and Evercore ISI are acting as bookrunning managers for the offering. Raymond James is acting as co-manager for the offering.

The shares described above are being offered pursuant to a registration statement that was filed with the U.S. Securities and Exchange Commission (the SEC) on November 12, 2026 and became automatically effective upon filing. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on November 12, 2026. The final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and may be obtained, when available, by contacting: Leerink Partners LLC, Attn: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, or by telephone at (888) 474-0200, or by email at ecm.prospectus@evercore.com; or by accessing the SEC’s website at www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Vir Biotechnology, Inc.

Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN® dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a portfolio of preclinical programs across a range of oncologic malignancies.

Forward-looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “should,” “could,” “may,” “might,” “will,” “plan,” “potential,” “aim,” “expect,” “anticipate,” “promising” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding the completion of the public offering. Many factors may cause differences between current expectations and actual results, including, without limitation, risks and uncertainties related to the satisfaction of customary closing conditions related to the public offering. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on these forward-looking statements, which are based on Vir Biotechnology’s available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology’s actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in the section titled “Risk Factors” of Vir Biotechnology’s Quarterly Report on Form 10-Q, filed with the SEC on November 4, 2026, and in the preliminary prospectus supplement relating to the offering. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

Vir Biotechnology has exclusive rights to the universal PRO-XTEN® masking platform for oncology and infectious disease. PRO-XTEN® is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.

Contacts

Media
Caren Scannell

Director, Communications

cscannell@vir.bio

Investors
Kiki Patel, PharmD

Head of Investor Relations

kpatel@vir.bio

Resero Analytics Launches TurboLIMS to Accelerate Nonclinical Studies

Resero Analytics Launches TurboLIMS to Accelerate Nonclinical Studies




Resero Analytics Launches TurboLIMS to Accelerate Nonclinical Studies

Cloud-based LIMS supports efficient study execution within TurboPlatform, a unified platform spanning study design, data collection, scientific interpretation and reporting.


INDIANAPOLIS–(BUSINESS WIRE)–Resero Analytics today launched TurboLIMS, a cloud-based laboratory information management system for GLP and non-GLP studies in toxicology, pharmacology, pharmacokinetics and toxicokinetics. TurboLIMS is a core component of Resero’s TurboPlatform, a unified platform for study design, electronic data capture, reporting and SEND readiness. Data collected in TurboLIMS flow directly into TurboToxicology for analysis, interpretation and generation of interim and final reports.

“Choosing a new LIMS is an opportunity to improve how your laboratory works,” said Dave Watson, PhD, Founder and Chief Executive Officer of Resero Analytics. “Your investment should deliver greater laboratory efficiency, faster access to study results and a shorter path from data collection to high-quality reports.”

TurboLIMS uses the study protocol to drive scheduling, sample labeling and electronic data collection. This eliminates redundant data entry common to legacy LIMS and helps laboratory teams execute studies efficiently and consistently while maintaining traceability from planned activities to recorded results.

“Study directors need confidence that what they approved in the protocol is what technicians actually execute,” said Taylor Scott, Product Manager at Resero Analytics. “TurboLIMS gives them visibility into what has been completed, what remains and what needs attention. Technicians have the study information they need to carry out activities accurately, while study directors can monitor progress and focus their attention where it is needed.”

That control extends to instrument data and sample identification. TurboLIMS transfers results from hematology, coagulation, chemistry and urinalysis analyzers directly into the study record, mapped to the appropriate parameters and species. Laboratory balances similarly transmit body weights into electronic data capture forms. Configurable sample labels use study, animal, sample and collection information already recorded in TurboLIMS, helping teams maintain accurate identification throughout sample collection and handling.

“An instrument result becomes useful study data when it is tied to the correct animal, study activity and timepoint,” said Anil Gunturu, Chief Technology Officer at Resero Analytics. “TurboLIMS preserves that context as data move from laboratory instruments into the study record, giving scientists a reliable basis for reviewing results, interpreting findings and preparing reports.”

Scientists and technicians at Envol Biomedical helped define TurboLIMS requirements and tested workflows in their laboratory. Their experience conducting GLP toxicology and non-GLP discovery studies helped shape the software around the practical needs of laboratory teams and the demands of both regulated and discovery research.

“Laboratory software has to work for the scientists and technicians who rely on it every day,” said Jake McDonald, PhD, Chief Executive Officer of Envol Biomedical. “Our team helped shape TurboLIMS around the realities of running studies. It helps our scientists execute studies faster and more efficiently while maintaining the quality and traceability our customers expect.”

TurboLIMS supports GLP-regulated and non-GLP research with role-based access, electronic signatures and comprehensive audit trails designed to support 21 CFR Part 11 compliance. Corrections preserve change history and require renewed signatures, maintaining accountability throughout study execution. Built from the outset with CDISC SEND standards in mind, TurboLIMS also captures study data using controlled terminology and a structure that supports SEND package generation with minimal manual effort. SEND dataset export is planned for 2027, including support for core requirements of SENDIG 4.0.

TurboLIMS is commercially available now to pharmaceutical and biotechnology companies and contract research organizations conducting GLP and non-GLP in vivo studies.

To schedule a TurboLIMS demonstration, visit reseroanalytics.com.

About Resero Analytics

Resero Analytics develops TurboPlatform, a unified, cloud-based software platform for nonclinical research. Its applications include TurboLIMS, TurboToxicology, TurboPKTK and TurboBioA. Together, they support study design, execution, scientific analysis and regulatory reporting. Resero serves pharmaceutical and biotechnology companies and contract research organizations. Learn more at reseroanalytics.com.

TurboPlatform, TurboLIMS, TurboToxicology, TurboPKTK and TurboBioA are trademarks of Resero Analytics.

Contacts

Media Contact
Dave Watson

marketing@reseroanalytics.com

I2Pure Scientists Identify a Reliability Gap in Iodine Antiseptics

I2Pure Scientists Identify a Reliability Gap in Iodine Antiseptics




I2Pure Scientists Identify a Reliability Gap in Iodine Antiseptics

New research published in ACS Omega reveals that traditional iodine antiseptics deliver miniscule quantities of free molecular iodine, the only biocidal agent in such products, and points to techniques to close the reliability gap.


ASHBURN, Va.–(BUSINESS WIRE)–I2Pure Corp., an iodine technology company advancing free molecular iodine (I₂) research and technology for health and biosafety applications, today announced the recent publication of a new peer-reviewed study led by its senior scientists, Ilker S. Bayer, Ph.D., and Jack Kessler, Ph.D., in ACS Omega, a journal of the American Chemical Society. View profile information about Drs. Bayer and Kessler (https://i2pure.com/PR-I2Pure-Peer-Reviewed-Study-PPM-Gap.shtml) here.

The study, “Transport of Molecular Iodine from Antiseptic Iodophors across Hydrophilic–Lipophilic Interfaces: Influence of Phospholipids,” reveals empirical evidence on a question with direct clinical relevance: how much free I₂ in a povidone-iodine (PVP-I) antiseptic is actually available to fight pathogens, and what can be done to maximize its availability.

“Healthcare has long relied on a single indicator of iodophor strength — titratable iodine — to describe antiseptic capability,” said Dr. Bayer, lead author of the study and Chief Scientist at I2Pure. “But that number doesn’t tell you how much free molecular iodine, the actual active antimicrobial agent, is unbound and available to provide antiseptic efficacy. Our data puts hard numbers behind that gap for the first time and reveals that traditional PVP-I formulations deliver miniscule levels of free molecular iodine. The balance of the iodine is so chemically bound to its carrier that it is not available to serve any antimicrobial purpose.”

Key Findings

Using a heptane-water interface model designed to mimic biological hydrophilic-lipophilic conditions, the research team tested five commercial PVP-I formulations and one dextrin-iodine complex, each standardized to 1% titratable iodine. Among the findings:

  • At full strength, standard PVP-I formulations released only about 4% of their titratable iodine across the interface — consistent with prior literature indicating that more than 99% of the iodine in PVP-I remains chemically bound and unavailable.
  • Diluting PVP-I solutions 8- to 10-fold temporarily increases the release of free I₂.
  • The dextrin-iodine (cadexomer-iodine) complex tested consistently outperformed the PVP-I formulations, achieving more rapid and incremental iodine release across nearly every condition studied.
  • The presence of phospholipids — representative of components found in biological membranes and bacterial cell walls — enhanced iodine transport, confirming the strong lipophilicity of molecular iodine and suggesting a charge-transfer interaction between free I₂ and lipids that may help explain its antimicrobial mechanism at the cellular level even when only small quantities of free I₂ are available.
  • Release kinetics were successfully modeled using Weibull and Michaelis-Menten mathematical frameworks (R² > 0.988), giving researchers a quantitative basis for comparing and optimizing iodophor formulations going forward.

“What stood out to me is how consistent the pattern was across different formulations and conditions,” said Dr. Kessler, co-author and Chief Scientific Officer at I2Pure. “Carrier chemistry and dilution ratio aren’t minor formulation details — they’re the difference between an antiseptic that delivers meaningful free iodine and one that mostly holds onto it. That has real implications for how these products are used in clinical settings.”

Why It Matters

Healthcare providers rely on iodine formulations for myriad applications, from topical antisepsis to surgery preparation to intraoperative rinses. If “titratable iodine” is an unreliable indicator of iodophor strength, many healthcare providers may be using these formulations based upon false confidence, resulting in a reliability gap. Because free I₂ — not bound or complexed iodine — is the active biocide in these products, understanding the gap between titratable and free I₂ has implications for antiseptic formulation, clinical dilution protocols, and infection-control practice across healthcare, including but not limited to topical, surgical, and wound-care settings. Future iodophor products will benefit from a structure that maximizes the availability of free I₂, closing the reliability gap that may exist in the use of PVP-I or other complexed iodine products.

The ACS Omega publication is the latest in a series of recent peer-reviewed publications from I2Pure’s science team. Previous publications include a University of California San Diego study confirming the antimicrobial performance of I2Pure’s molecular iodine formulations against multidrug-resistant pathogens (published in Antimicrobial Agents and Chemotherapy) and a comprehensive review of cellulose-based drug delivery systems authored by Dr. Bayer (published in Polymers). For a full list of I2Pure publications, please visit i2pure.com.

About I2Pure

I2Pure is an iodine technology company dedicated to advancing health and biosafety through its patented, non-toxic molecular iodine solutions. I2Pure’s mission is to prevent pathogenic threats to the world. Its proprietary technology platform has potential applications across healthcare, industrial biosafety, consumer products, and food processing and can be delivered directly or through carriers in solutions, nanoparticles, polymers, and coatings.

View the I2Pure website for more information or contact the company at info@i2pure.com.

Contacts

info@i2pure.com

Evidation Advances First-of-Its-Kind Flare-Triggered Proteomics Approach for Autoimmune Research

Evidation Advances First-of-Its-Kind Flare-Triggered Proteomics Approach for Autoimmune Research




Evidation Advances First-of-Its-Kind Flare-Triggered Proteomics Approach for Autoimmune Research

PACE pilot combines fully decentralized molecular sampling with longitudinal health data, laying the groundwork for new multimodal datasets to help researchers better understand disease mechanisms, identify potential drug targets, and develop more sophisticated models of immune-system activity.

SAN MATEO, Calif.–(BUSINESS WIRE)–Evidation, the leader in direct-from-participant real-world data and health research, today announced the completion of participant monitoring and biospecimen collection in its Precision in Autoimmune Condition Evidence (PACE) pilot, advancing a new approach to understanding the biology of autoimmune disease as it changes over time.


PACE is the first study of its kind in rheumatoid arthritis to combine fully decentralized, symptom-triggered blood collection across baseline, flare, and recovery states with longitudinal symptom reports, wearable measurements, and clinical history. By bringing these data sources together, the approach creates a new picture of autoimmune disease as it unfolds in everyday life, offering researchers a deeper understanding of the biological changes that accompany flares and recovery.

Designed as an initial pilot, PACE evaluated the feasibility of this sampling and data-linkage approach, with exploratory analyses planned to examine within-person changes in 251 inflammation-associated proteins across baseline, flare, and recovery states. Over approximately 60 days, 29 study participants contributed more than 1,300 daily symptom assessments that informed the timing of at-home blood collection. The study also included baseline genetic sampling.

PACE builds on Evidation’s temporal proteomics platform, introduced in January 2026, with participants recruited from the company’s autoimmune research cohort. Launched in November 2025, the cohort engages individuals living with autoimmune conditions through daily flare assessments, periodic surveys, and linked wearable and clinical data. Built on Evidation’s direct, ongoing relationships with more than 100,000 individuals diagnosed with autoimmune conditions, the cohort provides a foundation for expanding event-triggered molecular sampling beyond the initial pilot. As of October 2026:

  • More than 4,400 individuals are currently participating in the cohort across conditions including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Sjögren’s disease, inflammatory bowel disease, and multiple sclerosis, contributing longitudinal data on symptoms, treatments, and disease impact.
  • More than 3,200 participants have completed at least 30 daily flare assessments, and more than 1,500 have reported at least one qualifying flare episode, with detailed symptom data captured during those episodes.
  • More than 1,200 individuals have wearable observations around reported flare episodes, with a subset having linked electronic health records, enabling researchers to examine changes in symptoms and physiology alongside clinical history.

“Some of the most important changes in autoimmune disease happen between clinical visits, when researchers rarely capture biological data alongside detailed symptoms,” said Leslie Oley Wilberforce, CEO of Evidation. “Our ambition is to bring those moments into view by connecting molecular biology with how disease unfolds in people’s daily lives, at scale. PACE is creating a first-of-its-kind view of the biological changes surrounding rheumatoid arthritis flares and recovery. We’re excited to expand this work across our growing autoimmune cohort to build a differentiated resource that advances the development of new treatments for autoimmune disease.”

Evidation will share more about its autoimmune research platform during Fierce Biotech at London Life Sciences Week on November 17, 2026, in London, where Chief Medical Officer Sunny Khan, MPH, MBChB, MRCGP, will be speaking.

Life sciences partners interested in exploring potential collaboration can contact partner@evidation.com.

About Evidation

Evidation is redefining real-world data through direct, interactive relationships with millions of individuals. Through continuous engagement, Evidation captures longitudinal data to provide a more complete picture of health, including patient-reported and functional outcomes, connected device data, permissioned clinical records, and biosamples. Its privacy-first platform supports a right person, right time approach to data collection, enabling faster research, stronger evidence, and better product decisions. Founded in 2012, Evidation is headquartered in California.

Contacts

Media Contact

Greg Bowyer

press@evidation.com

Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa

Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa




Emmaus Life Sciences Advances Middle East Strategy with Real-World Evidence Initiatives and Expansion into Africa

Gulf observational studies and Saudi institutional access initiatives aim to generate region-specific evidence on Endari® in sickle cell disease


Marketing authorizations across five Middle Eastern markets and new Libya partnership further strengthen international commercial presence

TORRANCE, Calif.–(BUSINESS WIRE)–Emmaus Life Sciences, Inc. (OTCQB: EMMA), a commercial-stage biopharmaceutical company focused on sickle cell disease (SCD), today announced the advancement of two real-world evidence (RWE) initiatives across the Gulf Cooperation Council (GCC) region and the signing of an exclusive distribution agreement in Libya, marking the company’s entry into North Africa.

The initiatives are intended to generate additional real-world evidence on the use of Endari® (prescription L-glutamine oral powder) in routine clinical practice while supporting Emmaus’ broader international growth strategy.

These initiatives build upon an expanding body of international real-world evidence from the United States, France, Egypt, and elsewhere, where Endari has been associated with consistent improvements in key clinical and patient-centered outcomes. Across these reports, patients receiving Endari experienced reductions in VOC frequency, hospitalizations, transfusion burden, and other disease-related complications, together with improvements in patient-reported outcomes and quality of life measures. Favorable changes in hemoglobin levels and other hematologic parameters have also been observed. Collectively, these findings, reported across both short-term and long-term follow-up periods, provide important context for evaluating treatment outcomes in routine clinical practice.

The RWE program includes an ongoing up to 240-patient Gulf observational study across the United Arab Emirates (UAE), Oman, Bahrain, and Kuwait, together with clinical outcomes data generation activities across participating military healthcare institutions in Saudi Arabia. The initiatives are designed to evaluate treatment outcomes and patterns of care among patients receiving Endari in real-world clinical settings.

Primary and secondary endpoints include annual rates of vaso-occlusive crises (VOCs), hospitalization frequency and duration, incidence of acute chest syndrome (ACS), and blood transfusion requirements. The studies are expected to be completed over approximately two years, with findings evaluated following data collection and analysis.

Sickle cell disease remains a significant public health burden across the Gulf region, particularly in Saudi Arabia, Bahrain, and Oman. Despite advances in patient care, recurrent VOCs, hospitalizations, and long-term complications continue to impact patients, caregivers, and healthcare systems. Published studies have also highlighted variability in disease prevalence, clinical characteristics, and treatment practices across the region, underscoring the need for additional locally generated evidence.

By evaluating Endari in routine clinical practice, the initiatives aim to provide healthcare professionals and decision-makers with region-specific insights into treatment utilization and clinical outcomes, complementing data from randomized clinical trials.

“Real-world evidence plays an increasingly important role in understanding how therapies perform in routine clinical practice,” said Willis Lee, Chief Executive Officer of Emmaus Life Sciences. “Through collaboration with healthcare institutions across the Gulf region, these initiatives are intended to generate meaningful regional data on treatment patterns and clinical outcomes in patients with sickle cell disease while supporting our broader international growth strategy.”

Locally generated evidence from governmental and military healthcare settings may help inform Pharmacy and Therapeutics (P&T) committee evaluations, reimbursement assessments, physician education efforts, and broader patient access discussions.

In parallel with its clinical research initiatives, Emmaus continues to expand its commercial footprint across the Middle East and North Africa.

The company has obtained marketing authorization for Endari in the UAE, Qatar, Kuwait, Bahrain, and Oman. In Saudi Arabia, Endari has secured institutional formulary inclusion at several major military medical centers involved in the management of sickle cell disease, supporting access through established hospital procurement and P&T pathways.

Emmaus has also entered into an exclusive distribution agreement in Libya with Al Wataniya Aldawliya, a member of Assada Company for Medical Equipment and Medicine (ACMEM), to support Ministry of Health tender participation and site registration activities, establishing the company’s first commercial presence in North Africa.

“Clinicians across the Gulf region have emphasized the importance of locally generated evidence in sickle cell disease,” said JB Choi, General Manager, Middle East and Africa, Emmaus Life Sciences. “These initiatives are intended to contribute meaningful real-world insights from routine clinical practice while reinforcing our commitment to patients, healthcare professionals, and healthcare systems throughout the region. At the same time, our expansion into Libya represents an important step in extending Emmaus’ international presence.”

About Endari®

Endari® (L-glutamine oral powder) is approved in the United States to reduce acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Endari is currently marketed in multiple international territories through Emmaus Life Sciences and its distribution partners.

About Emmaus Life Sciences

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company focused on the treatment and management of rare and orphan diseases, including sickle cell disease. The company markets Endari® and continues to evaluate opportunities to expand patient access in the United States and internationally.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended, regarding the potential efficacy of L-glutamine for the treatment of sickle cell disease based upon clinical observations. These forward-looking statements are subject to numerous assumptions, risks, and uncertainties that change over time, including the risks that observed clinical outcomes will be positive and that any positive outcomes observed cannot be replicated in large patient populations or will translate into improved sales of Endari® (L-glutamine oral powder), and the other risks and uncertainties disclosed in the company’s reports filed with the Securities and Exchange Commission, and actual results may differ materially. Such forward-looking statements speak only as of the date they are made, and Emmaus assumes no duty to update them, except as may be required by law.

Contacts

Company Contact:
Emmaus Life Sciences, Inc.,
pr@emmauslifesciences.com

Media Contact
Alexander Petti
Alexander@TakeOncommunications.com
201-978-4882

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application

Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application




Clene Nanomedicine Partners with Veristat to Reduce Biostatistical Output Time by 80% for ALS New Drug Application

Veristat’s InStat™ delivers submission-ready tables, listings, and figures (TLFs) in one week using validated statistical engines, shortening the critical path from database lock to submission

SOUTHBOROUGH, Mass.–(BUSINESS WIRE)–VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, announced that it has partnered with Clene Nanomedicine to cut the time to deliver biostatistical outputs for a pivotal ALS drug application submission by 80%. Veristat reduced the time from study data to validated tables, listings and figures (TLFs) from up to six weeks to just one week. Clene, a late-stage biotech company, leveraged Veristat’s recently launched InStat™ platform, the industry’s first zero-code, fully automated solution to accelerate clinical trial processes.


Biostatistical TLFs sit on the critical path for submissions, yet most sponsors rely on antiquated processes that involve slow, manual workflows to produce them, making post-database lock one of the biggest bottlenecks to regulatory approval. To remove this barrier, Veristat uses its AI-enhanced platform to compress the timeline to submission-ready TLFs from weeks to days, with every output validated by statistical engines, fully traceable, and reviewed by Veristat expert biostatisticians.

For Clene, InStat delivered lightning-fast neurofilament light (NfL) biomarker analyses at the center of its New Drug Application for CNM-Au8 in amyotrophic lateral sclerosis (ALS), submitted in October 2026 under the accelerated approval pathway. When the volume of analyses required for the filing expanded beyond the original plan, InStat allowed the company to take on the added work and still submit in 2026.

“Veristat moved at unprecedented speed, eliminating weeks of hand-programming that is also the source of most errors,” said Rob Etherington, CEO of Clene Nanomedicine. “Every minute from database lock to submission matters. InStat enabled us to move from locked data to reviewable NfL biomarker tables in days, allowing for concurrent review and verification of the outputs instead of waiting until the end of a long cycle. That kind of speed, with the rigor we require, is what lets us keep pace with the urgency of ALS.”

At study close, sponsors can wait months for biostatisticians to manually analyze volumes of study data. Such delays to approval can cost sponsors $500,000 or more a day in potential, unrealized sales while patients remain burdened by their disease. Veristat’s InStat platform dramatically accelerates time to approval and helps sponsors realize market gains earlier by leveraging AI agents that turn biostatisticians’ descriptions into precise specifications. Those specifications drive a library of validated statistical engines that perform every analytical step – enabling the speed of automation without the risk or regulatory exposure of LLM-generated analysis code. And because InStat is system-agnostic, sponsors can use their preferred electronic data capture system and maintain their unique formatting.

Veristat’s work for Clene spanned a dozen deliverables, each with its own statistical analysis plan, and the company is now seeing the same results on two studies for a second sponsor.

“Everyone hoped AI would bring speed, but quality may be the bigger story,” said Kyle McBride, Veristat Vice President of AI & Innovation. “In every side-by-side comparison with traditional hand programming, any discrepancies traced back to the manual side, never to InStat. An error in an NDA puts an approval at risk. While much of the industry is still working on either speed, quality, or compliance, we’ve solved all three. Faster used to mean riskier. Not anymore, and that means new therapies can reach patients sooner.”

To learn more about InStat, visit https://www.veristat.com/instat.

About Veristat

Veristat is a full-service contract research organization and consultancy with 30+ years of experience and deep expertise in rare disease, neurological disease, oncology, and other complex modalities. Veristat integrates strategic planning, regulatory insight, data analysis, medical writing, and trial execution to overcome one-of-a-kind challenges and accelerate success. The company has supported more than 500 regulatory submissions globally. From early planning through approval, Veristat delivers tailored solutions and leverages advanced technologies that drive meaningful outcomes for patients worldwide.

Contacts

Media Contact:
Lisa Barbadora, Barbadora INK for Veristat

+1 (610) 420-3413

lbarbadora@barbadoraink.com

DIAGENS Leads in Two Major Global AI Benchmarks and Extends Chest and Abdominal CT Analysis to 509 Imaging Targets, Ushering in a New Era for Medical Imaging AI

EQS Newswire / 12/11/2026 / 22:30 UTC+8

Model-as-a-Service revenue grew 101.1% year over year in the first half of 2026.

Hong Kong, November 12, 2026 — DIAGENS (HKEX: 2526) today announced benchmark results for iMed-6.0, the latest generation of its iMedImage® medical imaging foundation model, and introduced a CT model designed to analyze 509 diseases and imaging findings. In MedBench’s multimodal API evaluation, iMed-6.0 Thoth ranked first and Aegis second overall, and the two models also placed first and second, respectively, in each of the three core categories. Thoth also surpassed the highest overall score previously reported on the Massive Multi-discipline Multimodal Understanding and Reasoning (MMMU) Benchmark .

The CT model, developed using iMed-6.0 Aegis, applies foundation-model capabilities to hundreds of chest and abdominal CT analysis tasks. Together with the company’s no-code model development tools, it demonstrates how a medical imaging foundation model can support both multi-task analysis and the development of specialty AI.

“Medical imaging foundation models make it possible for clinicians and hospitals to build and train specialty AI around the clinical challenges they know best. With no-code tools, they can adapt models for their own workflows and use those as AI copilots to support clinical decision-making,” said Dr. Ning Song, Chairman and CEO of DIAGENS.

Leading results in medical and multidisciplinary evaluation

MedBench is developed by Shanghai AI Laboratory and forms part of the OpenCompass evaluation ecosystem.

In MedBench’s multimodal API evaluation, Thoth scored 64.4 overall and Aegis scored 61.7. Both models ranked in the top two for medical visual perception and text extraction, cross-modal semantic understanding and reasoning, and clinical decision support and reasoning. In medical visual perception and text extraction, Thoth and Aegis scored 88.8 and 84.9. These were 20.3% and 15.0% higher, respectively, than the highest score of 73.8 among the other evaluated models.

On the MMMU benchmark, a multimodal academic benchmark spanning six broad domains and 30 subjects, Thoth achieved 66.2% overall accuracy, exceeding the previously published best result of 65.9%. In the Health & Medicine category, Thoth and Aegis achieved 74.9% and 71.1% accuracy, respectively, placing first and second in the benchmark evaluation.

One model for 509 CT Imaging Targets

Medical imaging is central to diagnosis. Imaging findings can change a diagnosis and guide decisions about further testing, treatment, and follow-up.

The CT model is designed for a defined imaging setting: non-contrast and contrast-enhanced CT examinations of the chest and abdomen. Within this application, it supports automated identification of 509 distinct diseases and imaging findings, covering 263 chest targets and 391 abdominal targets (with overlaps deducted in the total count).

In an internal validation using nearly 40,000 CT examination–report pairs from multiple hospitals, the model achieved a macro-averaged AUC of 0.855 for zero-shot classification across all 509 targets. For a subset of 249 key targets represented in internationally available public benchmarks, the model achieved a macro-averaged AUC of 0.930.

iMed-6.0 processes 3D imaging data, whole-slide pathology images, and temporal imaging data. It supports image interpretation, analysis of anatomy and lesions, and report drafting and review. For supported tasks, outputs can be linked back to specific slices or regions in the source images.

An industrialized R&D and production platform supports specialty AI at scale

DIAGENS combines these capabilities with iMedLoop™, its medical imaging AI development platform. The platform connects data preparation, model training, evaluation, deployment, and feedback. iMedMaaS® democratizes medical AI by enabling clinicians and hospitals to train, deploy, and scale custom models via a zero-code interface.

The same foundation model and standardized workflow can support the development and evaluation of specialty AI models across additional imaging tasks and clinical settings.

As of June 30, 2026, DIAGENS had undertaken 158 model projects and established R&D partnerships with 99 hospitals. Its products and services reached more than 400 healthcare institutions.

For the six months ended June 30, 2026, DIAGENS reported total revenue of RMB 108.7 million, up 21.0% year over year. Gross profit increased 14.0% to RMB 80.5 million, with a gross margin of 74.1%. Model-as-a-Service revenue reached RMB 94.5 million, up 101.1% year over year, and accounted for approximately 86.9% of total revenue.

 

About DIAGENS

DIAGENS (HKEX: 2526) develops medical imaging foundation models, software platforms for specialty AI development, and medical imaging AI products. Its iMedImage® model and iMedLoop™ platform support workflows from imaging data preparation and model training to evaluation, deployment, and feedback. The company works with hospitals and research institutions to develop AI for specific imaging tasks.

diagens.com

Media Contact

DUAN YU

DIAGENS Public Relations

duanyu@diagens.com

12/11/2026 Dissemination of a Financial Press Release, transmitted by EQS News.
The issuer is solely responsible for the content of this announcement.

Media archive at www.todayir.com

Novogenia to Contribute DNA Analytics and Personalized Dietary Supplements to Planned Clinical Study as Part of the 10XREVIV Initiative

Novogenia AG

/ Key word(s): Miscellaneous

Novogenia to Contribute DNA Analytics and Personalized Dietary Supplements to Planned Clinical Study as Part of the 10XREVIV Initiative

12.11.2026 / 13:00 CET/CEST

The issuer is solely responsible for the content of this announcement.


Novogenia to Contribute DNA Analytics and Personalized Dietary Supplements to Planned Clinical Study as Part of the 10XREVIV Initiative 

  • Planned study in Abu Dhabi combines genetic analysis with personalized nutrient supplementation for GLP-1 therapies
  • As part of the planned study, Novogenia will conduct DNA analyses, evaluate the results, and develop and produce personalized dietary supplements
  • The study design initially calls for 500 participants in Abu Dhabi
  • The 10XREVIV initiative is part of Novogenia’s international growth strategy 

Munich, November 12, 2026 – Novogenia AG (ticker symbol: 7V0), an international healthcare company focused on human genetics and the development of personalized products based on genetic insights, announces its exclusive participation as a technology and manufacturing partner in a planned clinical study as part of the 10XREVIV initiative in Abu Dhabi, United Arab Emirates.

For the study, Novogenia will conduct and evaluate DNA analyses and develop and manufacture personalized dietary supplements for study participants derived from the results. The planned study is part of the previously announced initiative involving healthcare partners M42, 10X Health, and REVIV Global.

“The 10XREVIV initiative is a key component of our international growth strategy. Through our participation in the planned study, we are contributing our core competencies in genetic analysis and the manufacture of personalized dietary supplements to a scientific study. The study aims to provide insights into the additional benefits that individually tailored nutritional support can offer to people receiving GLP-1 therapy. We see this as an important avenue for applying our technologies in the international healthcare market,” explained Dr. Daniel Wallerstorfer, CEO of Novogenia AG.

Personalized Nutrition as a Complementary Approach to GLP-1 Therapies

As part of the 10XREVIV initiative, Insights Research Organization and Solutions (IROS), a contract research organization (CRO) belonging to M42, and 10XREVIV have announced a clinical trial to investigate the potential benefits of personalized dietary supplements for patients receiving GLP-1 therapy. GLP-1-based medications are becoming increasingly important, particularly in weight management. The study design initially calls for the enrollment of 500 participants in Abu Dhabi. The focus is on determining the extent to which individually tailored nutritional support, alongside standard care, can positively influence the participants’ nutritional status, muscle and fat percentages, and well-being – particularly their quality of life and fatigue levels – as well as their consistent adherence to treatment.

As part of the planned study, Novogenia will conduct the participants’ DNA analyses and evaluate the results. Based on this, the company will develop and produce individually tailored dietary supplements for study participants. In doing so, Novogenia will make a significant contribution to the study’s technical implementation and production activities, leveraging its extensive expertise in human genetics and the development of personalized health products.

International Growth and New Market Potential 

The 10XREVIV initiative in Abu Dhabi is part of the previously announced international growth strategy for Novogenia’s core business. The company aims to expand the use of its genetic analysis technologies and personalized health products in international markets. Preparations already undertaken for the Middle East include adapting its products to regional requirements and successfully obtaining Halal certification.

The operational launch of the 10XREVIV initiative coincides with a period of strong growth in the global market for GLP-1-based therapies. According to market forecasts, the market is expected to rise from approximately $66 billion in 2025 to more than $185 billion by 2033[1]. As these therapies become more widely used, ensuring adequate nutrient intake is also gaining importance. A U.S. study published in 2025 involving more than 460,000 adults prescribed GLP-1 therapy documented that 22.4% experienced a nutrient deficiency or a related complication for the first time within one year. These findings highlight the importance of adequate nutrient intake during GLP-1 therapy, although other factors may also contribute to the development of nutrient deficiencies.

This creates new opportunities for Novogenia to apply its expertise in genetic analysis and the manufacturing of personalized dietary supplements to innovative care models and further expand its presence in the international healthcare market. Through its involvement in the planned study, Novogenia builds on the previously communicated strategic direction of the 10XREVIV initiative and strengthens its position as a technology and manufacturing partner in personalized healthcare.

About Novogenia AG

The “Novogenia Group” (i.e., Novogenia AG, including its subsidiaries and sub-subsidiaries), headquartered in Munich, Germany, is a European healthcare company, particularly active in the field of human genetics and the development of personalized products based on genetic analysis. The genetic analyses conducted in the company’s own laboratory are used in the diagnosis, treatment, and prevention of diseases, as well as in the production of individually tailored nutritional supplements and cosmetics. Novogenia also acts as a partner to physicians, therapists, pharmacists, nutritionists, and fitness trainers, helping to ensure treatment or support that is as optimal as possible for the patient’s or client’s needs by analyzing their respective genetic predispositions. In addition, Novogenia holds investments in innovative companies in the biotech, healthcare, and life sciences sectors. For more information, visit https://novogenia.com/novogenia-ag

Contact

Novogenia AG Media Contact
Brienner Str. 7 MC Services AG
80333 Munich Katja Arnold, Dr. Fotini Vogiatzi
Tel: +49 89 – 20 500 450 Phone: +49 89 – 210 228-0
investor.relations@novogenia.com novogenia@mc-services.eu

 

[1] https://www.grandviewresearch.com/industry-analysis/glp-1-receptor-agonist-market


12.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2433766  12.11.2026 CET/CEST

Bristol Myers Squibb Announces Evolution of Research & Development Organization

Bristol Myers Squibb Announces Evolution of Research & Development Organization




Bristol Myers Squibb Announces Evolution of Research & Development Organization

Cristian Massacesi to Lead Unified R&D Organization Designed to Accelerate Pipeline Momentum, Effective January 1, 2027

PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Patients—Bristol Myers Squibb (NYSE: BMY) today announced that Cristian Massacesi will lead a unified, end-to-end Research & Development organization, effective January 1, 2027. As part of this planned transition, Robert Plenge will remain with Bristol Myers Squibb in an advisory capacity through March 2027 to support a seamless transition before departing the company.


“Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth,” said Christopher Boerner, Ph.D., board chair and chief executive officer. “Under Cristian’s leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution. Increasingly, traditional boundaries between research and development are collapsing. This combined R&D organization sets us up to attract and retain the best talent, build critical capabilities, and better integrate new technology. I want to sincerely thank Robert for his extraordinary and lasting contributions to Bristol Myers Squibb, and his support on evolving the organization.”

“This is an exciting time at BMS, with immense scientific potential and an important opportunity to deliver on the promise of our pipeline while building what comes next,” said Cristian Massacesi, M.D., executive vice president, chief medical officer and incoming Head of R&D. “I’m grateful to Robert for his partnership, all he has contributed and the organization he has built. Our Research & Development teams are advancing exceptional science and uniting them as one team will enable us to translate our most promising discoveries into medicines for patients with greater speed and focus.”

“I am incredibly proud of what we accomplished together in Research at Bristol Myers Squibb,” said Robert Plenge, M.D., Ph.D., executive vice president, chief research officer. “It has been an honor to work alongside such exceptional scientists in advancing our mission. Cristian and I developed this new R&D structure in partnership, and I’m confident it is the right path forward for BMS and, most importantly, our patients.”

Effective January 1, 2027, the unified R&D organization will bring together Bristol Myers Squibb’s scientific and clinical expertise as one organization, strengthening collaboration from discovery through development. By combining the strengths of its teams, BMS aims to advance its pipeline with greater speed, sharper focus and a shared commitment to delivering for patients.

About Bristol Myers Squibb: Transforming Patients’ Lives Through Science

At Bristol Myers Squibb, our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. We are pursuing bold science to define what’s possible for the future of medicine and the patients we serve. For more information, visit us at BMS.com and follow us on LinkedIn, X, YouTube, Facebook and Instagram.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, that the expected benefits of the organizational changes described in this press release may not be realized. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2025, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.

corporate financial-news

Contacts

Bristol Myers Squibb


Media Inquiries:
media@bms.com

Investors:
investor.relations@bms.com

Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms

Pentixapharm Holding AG / Key word(s): Other

Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms

12-Nov-2026 / 10:07 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


12 November 2026

Disclosure of inside information pursuant to Article 17 of Regulation (EU) No 596/2014

 

Pentixapharm Holding AG extends drawdown period and term of its convertible bond with Eckert & Ziegler SE to 2030 with adjusted terms

Pentixapharm Holding AG (the “Company”) today entered into an agreement with Eckert & Ziegler SE (“EZAG”), as sole bondholder, to amend the 4.00% Corporate Convertible Bond 2024/2027 with an aggregate principal amount of EUR 18.5 million (the “Convertible Bond”) (the “Amendment Agreement”). The term of the Convertible Bond is extended from 31 December 2027 to 31 December 2030. The Company may now call for payment of the issue price of the 27 bonds not yet issued, with an aggregate principal amount of EUR 13.5 million, until 30 June 2030. In addition, the Company obtains the right to redeem the Convertible Bond early at its principal amount plus accrued interest. The extension increases the Company’s financial flexibility: repayment of the bonds already issued, with a principal amount of EUR 5.0 million, is deferred by three years, and further funds remain available for drawdown until mid-2030. In return, the interest rate increases from 4.00% to 6.00% p.a. as of 1 January 2027. In future, the conversion right may in principle be exercised at any time during the term. Furthermore, the Company undertakes to grant security for other bonds or comparable capital market liabilities only if the Convertible Bond participates equally in such security or receives equivalent security. The Company will also ensure this for its subsidiaries, in which it holds more than 85% of the equity interests or voting rights, as well as for Pentixapharm AG and all subsidiaries that currently own intellectual property belonging to the issuer or Pentixapharm AG or have been granted exclusive licenses to such intellectual property.

To cover the conversion rights arising from the aggregate principal amount of the Convertible Bond in full with conditional capital, the Management Board and the Supervisory Board intend to propose an increase in the conditional capital to the 2027 Annual General Meeting. Until then, the Company may, in accordance with the terms and conditions of the Convertible Bond, service conversion rights to the extent they exceed the existing conditional capital, in particular from authorized capital, by delivering treasury shares or by cash settlement.

The value of the Amendment Agreement amounts to approximately EUR 3.7 million in total. It was determined, without a separate valuation of the other amendments, on the basis of the Company’s increased maximum interest expense for the Convertible Bond over the extended term, assuming the issuance of all 37 bonds.

The Company treats EZAG as a related party. The Chairman of the Company’s Supervisory Board, Dr. Andreas Eckert, is also Chairman of EZAG’s Supervisory Board. Dr. Harald Hasselmann, a member of the Company’s Supervisory Board, is also Chairman of EZAG’s Management Board. Eckert Wagniskapital und Frühphasenfinanzierung GmbH (“EWK”) holds more than 30% in each of the Company and EZAG. Dr. Andreas Eckert holds 49.6% of EWK and is its managing director.

The Management Board and the Supervisory Board of the Company have approved the amendment of the terms and conditions. Dr. Andreas Eckert and Dr. Harald Hasselmann did not participate in the resolution and abstained from voting.

 

12 November 2026

 

Pentixapharm Holding AG, Berlin

The Management Board

Contact: ir@pentixapharm.com

Pentixapharm Holding AG, Robert-Rössle-Straße 10, 13125 Berlin, Germany

ISIN: DE000A40AEG0

Stock exchange: Regulated Market of the Frankfurt Stock Exchange (Prime Standard)

 

 

End of Inside Information


12-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: Pentixapharm Holding AG
Robert-Rössle-Straße 10
13125 Berlin
Germany
E-mail: info@pentixapharm.com
Internet: https://www.pentixapharm.com/
ISIN: DE000A40AEG0, DE000A383RV0
WKN: A40AEG
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate BSX
LEI Code: 3912005VBOVXNDXEQZ36
EQS News ID: 2433666

 
End of Announcement EQS News Service

2433666  12-Nov-2026 CET/CEST